0001209191-20-010541.txt : 20200219 0001209191-20-010541.hdr.sgml : 20200219 20200219163349 ACCESSION NUMBER: 0001209191-20-010541 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200217 FILED AS OF DATE: 20200219 DATE AS OF CHANGE: 20200219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kewalramani Reshma CENTRAL INDEX KEY: 0001735944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20630286 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-17 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001735944 Kewalramani Reshma C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 EVP and CMO Common Stock 2020-02-17 4 F 0 944 241.50 D 34341 D Common Stock 2020-02-18 4 S 0 120 241.71 D 34221 D Common Stock 2020-02-18 4 S 0 540 242.62 D 33681 D Common Stock 2020-02-18 4 S 0 134 243.76 D 33547 D Common Stock 2020-02-18 4 S 0 260 244.94 D 33287 D Common Stock 2020-02-18 4 S 0 129 245.75 D 33158 D Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $241.71 (range $241.24 to $242.02). Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.25 to $243.21). Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.25 to $244.08). Open market sales reported on this line occurred at a weighted average price of $244.94 (range $244.36 to $245.32). Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.36 to $245.86). /s/ Omar White, Attorney-in-Fact 2020-02-19